ப்ரொஃபெஸர் துணி அன்று News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ரொஃபெஸர் துணி அன்று. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ரொஃபெஸர் துணி அன்று Today - Breaking & Trending Today

New blood test can accurately detect 50 types of cancer before symptoms emerge


New blood test can accurately detect 50 types of cancer before symptoms emerge
Final results from a study of a blood test that can detect more than 50 types of cancer have shown that it is accurate enough to be rolled out as a multi-cancer screening test among people at higher risk of the disease, including patients aged 50 years or older, without symptoms.
In a paper published in the leading cancer journal
Annals of Oncologytoday (Friday), researchers report that the test accurately detected cancer, often before any symptoms arose, while having a very low false positive rate. The test also predicted where in the body the cancer is located with a high degree of accuracy, which could help doctors choose effective diagnostic tests. ....

France General , United States , United Kingdom , Fabrice Andr , Institut Gustave Roussy , Eric Klein , Emily Henderson , United Kingdom National Health Service , Grail Inc , Kidney Institute , Study First Author , Glickman Urological , Cleveland Clinic , Circulating Cell Free Genome Atlas , National Health Service , North America , Professor Fabrice Andr , பிரான்ஸ் ஜநரல் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , துணி அன்று , எரிக் க்ளீன் , எமிலி ஹென்டர்சன் , ஒன்றுபட்டது கிஂக்டம் தேசிய ஆரோக்கியம் சேவை , க்ரேல் இன்க் , கிட்நீ நிறுவனம் ,

SLA Resin Market Research Report - Global Forecast to 2024 - Cumulative Impact for COVID-19 Recovery


Global Banking & Finance Review® is a leading financial portal and Print Magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
Copyright © 2010-2021 GBAF Publications Ltd - All Rights Reserved.
We use cookies to enhance your visit, personalise our content, social media features, ads & to analyse our traffic. You consent to our cookies if you continue to use our website. AcceptReject
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. ....

France General , San Antonio , United States , Dave Fredrickson , Daiichi Sankyo , Fabrice Andr , Daiichi Sankyos , Head Of Research , Daiichi Sankyo Company , Oncology Development , World Health Organization , European Commission , Clinical Development Program , Department Of Medical Oncology , Daiichi Sankyo Group , European Union , Daiichi Sankyo Company Ltd , European Medicines Agency , Professor Fabrice Andr , Medical Oncology , Gustave Roussy Cancer Campus , Antonio Breast Cancer , New England Journal , Gilles Gallant , Senior Vice President , Global Head ,

ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer


Press release content from Business Wire. The AP news staff was not involved in its creation.
ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer
January 20, 2021 GMT
Daiichi Sankyo Company, Limited
(hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU ® (trastuzumab deruxtecan) has been granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens.
In Europe, approximately 531,000 cases of breast cancer in women are diagnosed annually, with an estimated one in five cases being HER2 positive. 1,2,3 The impact of the disease is significant, with breast cancer responsible for more than 141,000 deaths per year in Europe. 1 ....

France General , San Antonio , United States , Dave Fredrickson , Masashi Kawase , Daiichi Sankyo , Daiichi Sankyo Europe Gmb , Fabrice Andr , Melo Gagliato , Head Of Research , Daiichi Sankyo Company , Oncology Development , Daiichi Sankyo Inc , European Commission , World Health Organization , Clinical Development Program , Daiichi Sankyo Co Ltd , Department Of Medical Oncology , Daiichi Sankyo Group , European Union , European Medicines Agency , Daiichi Sankyo Company Ltd , National Comprehensive Cancer Network , Sankyo Company , Professor Fabrice Andr , Medical Oncology ,